FineMark National Bank & Trust Raises Stake in Novo Nordisk A/S (NVO)
FineMark National Bank & Trust increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 88.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 8,499 shares of the company’s stock after purchasing an additional 3,999 shares during the quarter. FineMark National Bank & Trust’s holdings in Novo Nordisk A/S were worth $392,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of NVO. We Are One Seven LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $46,000. Highwater Wealth Management LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $49,000. Lavaca Capital LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $52,000. CWM LLC lifted its stake in Novo Nordisk A/S by 273.7% in the fourth quarter. CWM LLC now owns 1,390 shares of the company’s stock valued at $64,000 after buying an additional 1,018 shares during the period. Finally, Enlightenment Research LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $97,000. 6.85% of the stock is currently owned by institutional investors and hedge funds.
Shares of Novo Nordisk A/S stock opened at $49.93 on Tuesday. Novo Nordisk A/S has a 1 year low of $41.23 and a 1 year high of $54.56. The stock has a market capitalization of $123.03 billion, a price-to-earnings ratio of 19.81, a price-to-earnings-growth ratio of 2.31 and a beta of 0.68.
Several research firms have weighed in on NVO. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. Barclays restated a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 5th. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Friday, February 1st. They issued an “equal weight” rating for the company. Handelsbanken downgraded Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price target for the company. in a report on Monday, February 4th. Finally, UBS Group restated a “buy” rating on shares of Novo Nordisk A/S in a report on Sunday, December 2nd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $52.31.
COPYRIGHT VIOLATION WARNING: “FineMark National Bank & Trust Raises Stake in Novo Nordisk A/S (NVO)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2019/02/19/finemark-national-bank-trust-raises-stake-in-novo-nordisk-a-s-nvo.html.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Further Reading: How to execute a trade ex-dividend strategy?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.